35 trials (keyword fallback)
Hemophilia A With Inhibitor
Primary: Reduction in the Burden of the Condition Including Treatment Burden, Bleed Frequency, Pain, Control, Freedom and Missed Opportunities) — 19; 10; 12; 9 participants
Hemophilia A
Primary: Annualized Number of Total Bleeds in On-demand Treatment Arm (Weeks 0 -36) and in Each Prophylaxis Arm (Weeks 10 - 36, Excluding Rescue Bleeds) - Part A, Main Trial…
Congenital Bleeding Disorder · Haemophilia A
Primary: Number of Adverse Events Reported — 58; 444; 8 Events
Hemophilia A
Primary: ITI Success — 1; 2; 6; 7 Participants
Congenital Bleeding Disorder · Haemophilia A
Primary: The Incidence Rate of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU)) — 0 N with Inhibitors / N with ≥50 EDs
Congenital Bleeding Disorder · Haemophilia B
Primary: Incidence of Inhibitory Antibodies Against Coagulation Factor IX (FIX) Defined as Titre Above or Equal to 0.6 Bethesda Units (BU) — 0; 0 Participants
Haemophilia B
Primary: Haemostatic Effect of Nonacog Beta Pegol When Used for Treatment of Bleeding Episodes During on Demand and Prophylaxis (PPX) — 203; 3; 26; 8 Bleeding Episodes
Congenital Bleeding Disorder · Haemophilia A
Primary: Haemostatic Effect During Surgery Evaluated by the Four-point Scale, Assessed by the Investigator/Surgeon at the Day of Surgery - Four-point Response Scale: Excellent…
Congenital Bleeding Disorder · Haemophilia A With Inhibitors · Haemophilia B With Inhibitors
Primary: Effective Bleeding Control Defined as no Additional Haemostatic Medication (Other Than Trial Product) Given — 22; 16; 318; 211 bleeding episodes
Congenital Bleeding Disorder · Haemophilia B
Primary: Incidence of Inhibitory Antibodies Against FIX Defined as Titre Above or Equal to 0.6 BU (Bethesda Units) — 0; 0; 0; 0 Patients with inhibitory antibodies
Haemophilia A
Primary: Number of Bleeding Episodes Per Year (Annualised Bleeding Rate) — 0.00; 0.00 Bleeding episodes per year
Severe Haemophilia A
Primary: Annualized Total Bleeding Rate of Individually Tailored Prophylaxis — 4.67; 58.08 Bleeding events per year (ABR) — p=<0.0001
Congenital Bleeding Disorder · Haemophilia A
Primary: Number of Participants With Inhibitory Antibodies Against Coagulation Factor VIII (FVIII) ≥0.6 Bethesda Units — 0; 0 Participants
Congenital Bleeding Disorder · Haemophilia A
Primary: The Incidence Rate of FVIII-inhibitors ≥0.6 BU: After Approximately 19 Months — 0.006; 0 Inhibitor rate
Hemophilia B
Primary: Mean Difference of Area Under the Curve (AUC): BeneFIX Compared to AlphaNine — 10.41 IU x hour/dL — p=0.77